Debiopharm Explained

Debiopharm
Type:Société Anonyme
Industry:Biopharmaceutical
Foundation:Lausanne, Switzerland (1979)
Founder:Dr Rolland-Yves Mauvernay(1922-2017)
Location:Lausanne, Switzerland
Area Served:Worldwide
Owner:Privately-held
Homepage:www.debiopharm.com

Debiopharm is a privately-held Swiss biopharmaceutical company mainly active in development and clinical testing of drug candidates.[1] It was founded in 1979 by Rolland-Yves Mauvernay.

History

Rolland-Yves Mauvernay founded Debiopharm in 1979 in Martigny, Switzerland.[2] In 1981, the Cytotech laboratory was created and after a few years it became Debio Recherche Pharmaceutique (R.P.), then Debiopharm Research & Manufacturing. Initially, the company worked on interferon and, in 1982, it began to focus on triptorelin, after having acquired the rights for its development from Tulane University.[3] Triptorelin is a Gonadotropin-releasing hormone agonist (GnRH agonist) that has been approved for several indications, including advanced prostate cancer and endometriosis.[4] [5] The first marketing authorization for this medication was obtained in France in 1986.[6]

In 1989, Debiopharm acquired the license for oxaliplatin, a diaminocyclohexane (DACH) platin, from Nagoya City University. The drug was first approved in Europe in 1996 and became a standard treatment in metastatic colorectal cancer.[7] Since launch, triptorelin and oxaliplatin have generated several billion dollars in revenue for the company.[8]

In 2004, after having occupied different premises in Lausanne, Debiopharm moved its headquarters to a new building: what became "Après-demain Forum" had been initially designed by architect Jean Tschumi as the headquarters commodity trading giant Andre and is a cultural property of national significance.[9]

In 2005, Debiopharm acquired the Canadian company H3 Pharma, rebranded Debiovision, to support the development and worldwide registration of its medicines.[10]

The company's business model relies on establishing partnerships and research agreements with other companies or universities to develop new molecules and run clinical trials before licensing them in case of success. It partnered for instance in 2009 with US-based MSM Protein Technologies to work on a new oncology treatment,[11] in 2011 with Yale University as part of an agreement to develop and commercialise medicine for autoimmune and inflammatory diseases,[12] in 2014 with German company Evotec to identify and develop compounds to treat a variety of cancers,[13] or with Canadian company Nobelex Biotech (also in 2014) to develop antibiotics targeting Neisseria gonorrhoeae and enteric species.[14]

In March 2021, Merck KGaA announced the acquisition of Debiopharm's xevinapant program in head and neck cancer for 900 million euros.[15]

Structure and subsidiaries

Debiopharm is the Life Science division of the holding company Après-demain (litt. "The Day after Tomorrow") with three subsidiaries active in drug development (Debiopharm International), drug manufacturing (Debiopharm Research & Manufacturing) and investment (Debiopharm Innovation Fund):[16] [17]

Until 2020, the subsidiary Debiopharm Investment SA managed the group's asset management activities.[28] This subsidiary was merged and its former activities are now directly taken over by the holding company Après-demain SA.[28]

Products

Debiopharm is known for the development of triptorelin and oxaliplatin, two drugs that became standards of care for the treatment of various types of cancer and are listed on the World Health Organization's List of Essential Medicines.[29] [30]

Currently marketed

Under development

Early-stage treatments being developed by Debiopharm are referred to by code names such as "Debio [+4 digit number]".[33] In 2020, Debiopharm signed a global license and research agreement with German biotech 3B Pharmaceuticals (3BP) to work on "Debio 0228", a treatment targeting the CAIX (Carbonic anhydrase 9) enzyme to fight the progression of cancer.[34] Other drug candidates under development include:

External links

Notes and References

  1. Web site: Debiopharm Group . Bloomberg . 2016-05-12.
  2. Web site: 2015-09-17 . Debiopharm investit. "J'ai fondé cette entreprise à Martigny", se souvient Rolland-Yves Mauvernay . Canal9 . fr.
  3. Web site: Spezialist für Entwicklung von Krebsmedikamenten – Klein und unbekannt, aber hochprofitabel Ein Generalunternehmer für die Pharmaindustrie . Finanz und Wirtschaft . 2002-04-03 . de.
  4. Guillaume Ploussard . Pierre Mongiat-Artus . Triptorelin in the management of prostate cancer . Future Oncology (London, England) . 2013. 9 . 1 . 93–102 . 10.2217/fon.12.158 . 23252566 .
  5. The efficacy and safety of triptorelin-therapy following conservative surgery for deep infiltrating endometriosis . 2022-02-04. 8812645 . Zhu . L. . Guan . Z. . Huang . Y. . Hua . K. . Ma . L. . Zhang . J. . Yang . D. . Perrot . V. . Li . H. . Zhang . X. . Medicine . 101 . 5 . e28766 . 10.1097/MD.0000000000028766 . 35119037 .
  6. Web site: Christian Hilscher . Triptorelin . 2017-03-23 . ArzneiNews . de.
  7. Web site: 2006-10-05 . Oxaliplatin - NCI . 2023-02-13 . www.cancer.gov . en.
  8. Web site: Bernard Tappy . Debiopharm Research and Manufacturing SA . In Vivo Magazine . 2013.
  9. Web site: Jean-Claude Péclet . 2004-10-20 . L'ancien siège d'André à Lausanne reprend vie grâce au succès de Debiopharm . Le Temps.
  10. Web site: Debiovision integrates into the Debio Group . Manufactiring Chemist . 2005-09-16.
  11. Web site: Debiopharm and MSM Protein Technologies sign oncology research agreement . Manufacturing Chemist . 2009-07-30.
  12. Web site: Debiopharm and Yale University sign worldwide agreement . Manufacturing Chemist . 2011-05-04.
  13. Web site: Evotec and Debiopharm to collaborate on development of new cancer treatment . Manufacturing Chemist . 2014-04-02.
  14. Web site: Debiopharm and Nobelex Biotech to develop antibiotics against N. Gonorrhoeae and enteric species . Manufacturing Chemist . 2014-07-01.
  15. News: 2021-03-01 . Merck agrees $1 billion deal with Debiopharm for head and neck cancer drug . en . Reuters . 2023-02-13.
  16. Web site: Après-demain SA . Business Monitor.
  17. Web site: Debiopharm continues fight against antibiotic resistance . Manufacturing Chemist . 2018-02-15.
  18. Web site: Debiopharm International . Bloomberg . May 12, 2016.
  19. Web site: fr . Nous voulons acquérir une nouvelle société . Le Temps . 2014-01-20.
  20. Web site: Debiopharm Research & Manufacturing . The Ark . 2016-05-15.
  21. Web site: fr . Modernisé, Debiopharm va prendre de l'ampleur . Le Nouvelliste . 2015-09-22.
  22. Web site: Debiopharm Research & Manufacturing SA information . Appollo.io.
  23. Web site: Enabling healthcare's digital future . Pharmaphorum Magazine . 2021.
  24. Web site: Carevive Systems Raises Series C Financing . Finsmes . 2020-02-14.
  25. Web site: VivoSense Exits Stealth Mode with a Big Series A Round . MDDI Online . 2022-03-30.
  26. Web site: Iktos raises € 15.5m Series A round to expand its artificial intelligence-based drug discovery technologies and solutions . Yahoo Finance . 2023-03-09.
  27. Web site: 2020-05-20 . Cancer-focused Elekta snaps up digital oncology startup Kaiku Health . 2023-05-24 . MobiHealthNews . en.
  28. Web site: Debiopharm Investment SA . Money House.
  29. Book: World Health Organization model list of essential medicines: 22nd list (2021) . ((World Health Organization)) . World Health Organization . 2021 . Geneva . 10665/345533 . WHO/MHP/HPS/EML/2021.02 . World Health Organization . free.
  30. Book: World Health Organization model list of essential medicines: 22nd list (2021) . ((World Health Organization)) . World Health Organization . 2021 . Geneva . 10665/345533 . WHO/MHP/HPS/EML/2021.02 . World Health Organization . free.
  31. Web site: Katie McQue . DebioPharm's Salvacyl launched in EU for sexual deviancy . Pharma Intelligence . 2009-06-26.
  32. Web site: Debiopharm extends its Eloxatin collaboration with Sanofi-Synthelabo . Pharma Biz . 2002-08-28.
  33. Web site: 2014-07-01 . Debiopharm and Nobelex Biotech to develop antibiotics against N. Gonorrhoeae and enteric species . Manufactiring Chemist.
  34. Web site: 2020-03-25 . Debiopharm and 3BP enter into global R&D deal for radioligand tech . The Pharma Letter.
  35. Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck . Future Medicine . 2022-02-17. 10.2217/fon-2021-1634 . free .
  36. News: 2021-03-01 . Merck agrees $1 billion deal with Debiopharm for head and neck cancer drug . en . Reuters . 2023-02-13.
  37. Afabicin, a First-in-Class Antistaphylococcal Antibiotic, in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Clinical Noninferiority to Vancomycin/Linezolid . 2020-09-21. 7508579 . Wittke . F. . Vincent . C. . Chen . J. . Heller . B. . Kabler . H. . Overcash . J. S. . Leylavergne . F. . Dieppois . G. . Antimicrobial Agents and Chemotherapy . 64 . 10 . e00250-20 . 10.1128/AAC.00250-20 . 32747361 .
  38. Web site: Hofland . Peter . 2020-03-06 . Debio 0123, a Potent WEE1 Inhibitor, to be Assessed in First-in-human, Dose-escalation Study . 2023-08-29 . Onco'Zine . en-US.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Debiopharm".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.